FMP
NASDAQ
5.06 USD
-1 (-19.76%)
Dr. Ahmed M. Hamdy M.D.
Healthcare
Biotechnology
https://vincerx.com
NASDAQ
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.
0001796129
US92731L1061
92731L106
260 Sheridan Avenue
650 800 6676
US
41
May 27, 2020
0001796129
NASDAQ
Biotechnology
Healthcare
92731L106
US92731L1061
US
5.06
0.76
1.09M
108.19M
-
0.61-9.372
0.39
-
-
-
-
-2.19
-
https://vincerx.com
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.